Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Progesterone

Summary

Persistence. It cannot be excluded that progesterone is persistent, due to the lack of data.

Bioaccumulation. It cannot be excluded that progesterone bioaccumulates, due to the lack of data.

Toxicity. It cannot be excluded that progesterone is toxic, due to the lack of data.

Risk. Progesterone (vaginal) is indicated as the only alternative for luteal phase support (in the formulary for Region Stockholm, Sweden, ed. note). The use of progesterone is considered to pose a low environmental risk.

 

Environmental information is missing on fass.se for progesterone (2025-04-15). The risk comes from the report from Goodpoint.

Detailed information

Report Goodpoint 2024

The report from Goodpoint 2024 aims to present an overall, comparative assessment for the treatment options recommended for all indications under the therapeutic area of ​​gynecology and obstetrics in the 2024 Wise list (the formulary for Region Stockholm, Sweden) containing either estrogens or progestogens + estetrol. The risk assessment does not aim to assess absolute or quantitative risk (which, for example, strongly depends on dilution in different recipients) but is primarily of a comparative nature, i.e., a ranking of the risk between different treatment options. For more information see the report.

Author: Health and Medical Care Administration, Region Stockholm